bezafibrate has been researched along with Muscle Disorders in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chin, MT; Heyman, A; Hornby, B; Jefferies, J; Pu, WT; Takemoto, C; Thompson, R; Vernon, HJ; Wang, S | 1 |
| Asahina, N; Egawa, K; Hayashi, H; Ishige, M; Isoe, T; Kawakami, S; Kobayashi, K; Kuzume, K; Miyakoshi, T; Nakamagoe, K; Oba, K; Ochi, F; Sameshima, K; Sato, N; Shiraishi, H; Tamaoka, A; Watanabe, A; Watanabe, K; Yamada, K; Yamaguchi, S; Yokoshiki, S | 1 |
| Andersen, KG; Gregersen, N; Hargreaves, IP; Heaton, R; Lund, M; Olsen, RKJ | 1 |
| Bilet, L; Bosma, M; Havekes, B; Hesselink, MK; Hoeks, J; Janssen, MC; Jorgensen, J; Paglialunga, S; Sauerwein, H; Schaart, G; Schrauwen, P; Schrauwen-Hinderling, VB; Smeets, JL; Sparks, L; van de Weijer, T; Wildberger, J; Zechner, R | 1 |
| Andersen, G; Laforêt, P; Madsen, KL; Preisler, N; Vissing, J; Ørngreen, MC | 1 |
| Bastin, J; Bonnefont, JP; Bresson, JL; Djouadi, F | 1 |
| Laforét, P; Vissing, J; Ørngreen, MC | 1 |
| Ding, Y; Li, X; Liu, Y; Ma, Y; Song, J; Wang, Q; Yang, Y | 1 |
| Harrington, M | 1 |
| Aubey, F; Bastin, J; Behin, A; Bonnefont, JP; Bresson, JL; Djouadi, F; Eymard, B; Gobin-Limballe, S; Laforêt, P; Mogenet, A; Ricquier, D; Romano, S; Vassault, A | 1 |
| Albert, V; Bentzinger, CF; Conjard-Duplany, A; Gangloff, YG; Handschin, C; Lin, S; Mazelin, L; Puigserver, P; Romanino, K; Rüegg, MA; Schaeffer, L; Zorzato, F | 1 |
| Eymard, B; Laforêt, P; Nicolino, M | 1 |
| Bock, KD; Heidemann, H | 1 |
| Galiana, J; Marchán, E; Montés, I; Pato, S | 1 |
| Bresolin, N; Ferrò, MT; Fortunato, F; Gagliardi, E; Messina, C; Mileto, G; Pitrone, F; Toscano, A; Vita, G | 1 |
| Ichikawa, M; Matsuyama, K; Nakai, A; Nishikata, M; Uchida, T | 1 |
| Fernández-Solá, J; Fueyo, J; Gómez Manzano, C; Pedro-Botet Montoya, J | 1 |
| Chan, MK | 1 |
3 review(s) available for bezafibrate and Muscle Disorders
| Article | Year |
|---|---|
Current and future treatment approaches for Barth syndrome.
Topics: Acyltransferases; Animals; Barth Syndrome; Bezafibrate; Cardiolipins; Cardiomyopathies; Clinical Trials as Topic; Enzyme Therapy; Genetic Therapy; Humans; Mice; Muscular Diseases; Neutropenia; Oligopeptides; Peroxisome Proliferator-Activated Receptors | 2022 |
[New approaches for the treatment of metabolic myopathies].
Topics: Bezafibrate; Carnitine O-Palmitoyltransferase; Glycogen Storage Disease; Humans; Hypolipidemic Agents; Metabolism, Inborn Errors; Mitochondrial Myopathies; Muscular Diseases | 2007 |
[Toxic myopathies related to the administration of hypolipidemic agents: are the drugs the only things responsible?].
Topics: Adult; Aged; Bezafibrate; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Lovastatin; Male; Muscular Diseases; Simvastatin | 1995 |
2 trial(s) available for bezafibrate and Muscle Disorders
| Article | Year |
|---|---|
Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Adolescent; Adult; Aged; Bezafibrate; Carnitine O-Palmitoyltransferase; Clinical Protocols; Congenital Bone Marrow Failure Syndromes; Cross-Over Studies; Fatty Acids; Female; Humans; Hypolipidemic Agents; Lipid Metabolism, Inborn Errors; Male; Middle Aged; Mitochondrial Diseases; Muscle, Skeletal; Muscular Diseases; Treatment Outcome; Young Adult | 2014 |
Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency.
Topics: Activities of Daily Living; Acyl-CoA Dehydrogenase, Long-Chain; Adult; Bezafibrate; Carnitine O-Palmitoyltransferase; Exercise Test; Female; Follow-Up Studies; Gene Expression Regulation, Enzymologic; Humans; Hypolipidemic Agents; Lymphocytes; Male; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; Muscular Diseases; Oxidation-Reduction; Oxygen Consumption; Pain; Palmitoyl Coenzyme A; Pilot Projects; Rhabdomyolysis; Treatment Outcome; Young Adult | 2010 |
13 other study(ies) available for bezafibrate and Muscle Disorders
| Article | Year |
|---|---|
Efficacy of bezafibrate for preventing myopathic attacks in patients with very long-chain acyl-CoA dehydrogenase deficiency.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Adult; Bezafibrate; Child; Congenital Bone Marrow Failure Syndromes; Female; Humans; Lipid Metabolism, Inborn Errors; Male; Mitochondrial Diseases; Muscular Diseases | 2021 |
Bezafibrate activation of PPAR drives disturbances in mitochondrial redox bioenergetics and decreases the viability of cells from patients with VLCAD deficiency.
Topics: Bezafibrate; Congenital Bone Marrow Failure Syndromes; Energy Metabolism; Fibroblasts; Humans; Hypolipidemic Agents; Lipid Metabolism, Inborn Errors; Mitochondria; Mitochondrial Diseases; Muscular Diseases; Oxidative Stress; Peroxisome Proliferator-Activated Receptors | 2021 |
Effects of bezafibrate treatment in a patient and a carrier with mutations in the PNPLA2 gene, causing neutral lipid storage disease with myopathy.
Topics: Adult; Alleles; Bezafibrate; Fatty Acids; Female; Humans; Hypolipidemic Agents; Lipase; Lipid Metabolism; Lipid Metabolism, Inborn Errors; Muscular Diseases; Mutation; Treatment Outcome | 2013 |
Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Bezafibrate; Carnitine O-Palmitoyltransferase; Congenital Bone Marrow Failure Syndromes; Fatty Acids; Heart Rate; Humans; Lipid Metabolism, Inborn Errors; Lipolysis; Metabolism, Inborn Errors; Mitochondrial Diseases; Muscular Diseases; Oxidation-Reduction; Treatment Outcome | 2015 |
No effect of bezafibrate in patients with CPTII and VLCAD deficiencies.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Bezafibrate; Carnitine O-Palmitoyltransferase; Congenital Bone Marrow Failure Syndromes; Fatty Acids; Humans; Lipid Metabolism, Inborn Errors; Lipolysis; Metabolism, Inborn Errors; Mitochondrial Diseases; Muscular Diseases | 2015 |
Very long-chain acyl-coenzyme A dehydrogenase deficiency in Chinese patients: eight case reports, including one case of prenatal diagnosis.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Acyl-CoA Dehydrogenases; Amniotic Fluid; Ascorbic Acid; Asian People; Bezafibrate; Carnitine; Case-Control Studies; China; Chromatography, Liquid; Congenital Bone Marrow Failure Syndromes; DNA, Complementary; Exons; Female; Genetic Testing; Heterozygote; Humans; Infant; Infant Formula; Infant, Newborn; Lipid Metabolism, Inborn Errors; Male; Mitochondrial Diseases; Muscular Diseases; Mutation, Missense; Neonatal Screening; Prenatal Diagnosis; Sequence Alignment; Sequence Analysis, DNA; Tandem Mass Spectrometry; Treatment Outcome; Triglycerides; Vitamin B Complex | 2015 |
Mice, mitochondria and myopathy.
Topics: Animals; Bezafibrate; Female; Mice; Mice, Knockout; Mitochondria; Mitochondrial Diseases; Muscular Diseases; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Trans-Activators; Transcription Factors | 2008 |
Myopathy caused by mammalian target of rapamycin complex 1 (mTORC1) inactivation is not reversed by restoring mitochondrial function.
Topics: Animals; Bezafibrate; Gene Expression Regulation; Glycogen; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Knockout; Mice, Transgenic; Mitochondria; Mitochondria, Muscle; Models, Genetic; Multiprotein Complexes; Muscle, Skeletal; Muscular Diseases; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Proteins; TOR Serine-Threonine Kinases; Trans-Activators; Transcription Factors | 2011 |
[Rhabdomyolysis with acute renal failure due to bezafibrate].
Topics: Acute Kidney Injury; Bezafibrate; Clofibrate; Clofibric Acid; Humans; Male; Middle Aged; Muscular Diseases | 1981 |
Bezafibrate-induced myopathy: no evidence for defects in muscle metabolism.
Topics: Bezafibrate; Biopsy; Carbohydrate Metabolism; Chronic Disease; Humans; Lipid Metabolism; Male; Middle Aged; Mitochondria, Muscle; Muscles; Muscular Diseases; Uremia | 1993 |
Enhanced myopathy following administration of hypolipidemic agents under urethane anesthesia.
Topics: Anesthesia; Animals; Bezafibrate; Calcium; Creatine Kinase; Hypolipidemic Agents; Lovastatin; Male; Muscular Diseases; Pravastatin; Rats; Rats, Wistar; Simvastatin; Urethane | 1997 |
[Bezafibrate-induced necrotizing myopathy].
Topics: Bezafibrate; Biopsy; Female; Humans; Middle Aged; Muscles; Muscular Diseases; Necrosis | 1991 |
Sustained-release bezafibrate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis.
Topics: Adolescent; Adult; Aged; Bezafibrate; Cholesterol, HDL; Coronary Disease; Delayed-Action Preparations; Diabetes Complications; Drug Evaluation; Female; Humans; Hypertriglyceridemia; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Muscular Diseases; Peritoneal Dialysis, Continuous Ambulatory | 1990 |